Pharmaceutical research & development company AbbVie (NYSE:ABBV) on Friday announced European Commission approval for SKYRIZI (risankizumab) for the treatment of moderately to severely active ulcerative colitis (UC).
SKYRIZI is targeted at patients who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
This marks its fourth approved indication in the European Union.
UC affects an estimated 5 million people globally. SKYRIZI demonstrated efficacy in achieving clinical remission and key secondary endpoints in Phase 3 trials.
Notably, the drug showed positive results in mucosal healing, particularly among patients without prior biologic therapy or JAK inhibitor failure. SKYRIZI's safety profile was consistent with previous studies.
AbbVie is leading SKYRIZI's global development and commercialisation under a collaboration with Boehringer Ingelheim.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member